semaglutide cardioprotective cardiovascular outcomes align more closely with attained dose than achieved weight loss SELECT Trial

Dr V Mohan, Chairman, Diabetes Specialities Centre, Chennai, analyses the far-reaching impact of weight loss drugs

Understanding the mechanism helps patients make informed decisions about long-term weight management

In individuals with advanced -cell dysfunction, supplementing insulin therapy with pramlintide, the first and currently only approved injectable short-acting selective analog of amylin, has demonstrated efficacy in enhancing both postprandial and overall glycemic control in both type 2 diabetes (T2D) and type 1 diabetes (T1D) without increasing the risk of hypoglycemia or weight gain

Explaining the Benefits of Primary Care

Personalized Plans for Effective Weight Management and a Healthier You

Surgery timing with GLP-1 therapy requires careful planning